Sentences with phrase «cancer test identifies»

The genTrue hereditary cancer test identifies those who have suspected heritable cancer syndrome.

Not exact matches

The genomic tests can quickly identify those who need further attention and reassure those who test negative for the cancer.

If you have a strong family history of breast cancer or other cancers, your doctor may recommend a blood test to help identify specific mutations in BRCA or other genes that are being passed through your family.

With new tests to identify women who are at heightened risk of breast cancer, new drugs aimed at preventing allergies, and the discovery of new genes that are key to the progression of conditions like Alzheimer's - to give just three examples - we are at the dawn of a whole new era:

«Also, performing a yearly fecal immunochemical test («FIT») is an effective screening method to identify those who need further evaluation and possible treatment to prevent the progression of colorectal cancer.»

«How melanoma tumors form: Team identifies drugs that halt skin cancer metastasis in lab tests.»

However, a blood test could be used as a first line of defense to identify patients with warning signs of cancer; these high - risk patients could then be referred for a colonoscopy to learn more.

«Starting with our cell model that mimics human pancreatic cancer progression, we identified released proteins, then tested and validated a subset of these proteins as potential plasma biomarkers of this cancer,» Zaret said.

Up until now, no single test could predict the severity of the cancer type - the current PSA test (Kallikrein 3), which is located near Kallikrein 6, only identifies the risk of prostate cancer, not the severity.

A blood test for colon cancer will never replace colonoscopy: once polyps are identified, a colonoscopy is still the best way to figure out where they're located so that they can be removed.

This new study demonstrated that the test can also be used to identify people with precancerous polyps — a finding that makes it potentially more useful for a screening test, since it may be able to identify cancer risk before the disease actually develops.

Scientists have developed a new test to identify patients who are at risk of suffering a relapse from testicular cancer.

«A large, recently published study examined the performance of a multitarget stool test that identifies several DNA abnormalities associated with colorectal cancer or precancerous adenomas.

Screening histories preceding cervical cancers (n = 623) and precancers (n = 5,369) were examined to assess the relative contribution of the Pap test and HPV test components in identifying cases.

The analysis found that HPV testing identified more women subsequently diagnosed with cancer and precancer than the Pap test.

A report in The Journal of Molecular Diagnostics describes a new blood test that can accurately and quickly identify genetic mutations associated with NSCLC, allowing clinicians to make earlier, individualized treatment choices — a step forward in personalized cancer treatment.

The commission concludes that the tumours likely to result from the tests — such as thyroid or brain cancer — either can not be identified by screening or can not be treated.

«We hope that our test will significantly improve the odds of survival of breast cancer patients by allowing doctors to identify the most effective but least toxic form of chemotherapy for each individual patient before the treatment begins.»

Exploiting the same pre-clinical model used for their studies, the researchers are testing the efficacy of this kind of drug candidates against cancer stem cells, and the possibility of identifying combination regimens with standard chemotherapies with minimized toxic effects, with the perspective of their possible application for the treatment of human breast cancer.

«We have effective screening tests for several cancers, which allow physicians and other health - care providers to identify the disease at an earlier stage — often before symptoms surface — when treatment is more likely to result in a cure,» said senior author of the report and IPHI Director Kenneth W. Kizer.

Pap tests can identify cervical precancer before it turns into cancer.

When tested on various cancer patient databases, iCAGES was found to be superior to other computational tools at predicting cancer drivers from personal genomes and at identifying beneficial treatment.

«Breath temperature test could identify lung cancer.»

Mutations in known breast cancer genes such as BRCA1 and BRCA2 are identified in only approximately 20 per cent of women who are offered genetic testing for familial breast cancer.

The test, which analyzes fluid from pancreatic cysts, can identify a common type of benign cyst that can't be differentiated by imaging alone from cysts that may progress to pancreatic cancer.

Scientists at the University of Exeter Medical School found that one in 60 people over the age of 60 who had invisible blood in their urine (identified by their GP testing their urine) transpired to have bladder cancer.

Tested on data from The Cancer Genome Atlas (TCGA), MEGENA identified novel regulatory targets in breast and lung cancers, outperforming other co-expression analysis methods.

The specificity of the testing strategy was 99.9 percent, meaning that only 0.1 percent of patients without cancer would be falsely identified as having the disease.

The AGA recommendation for tumor testing in all newly diagnosed cases of colorectal cancer to identify Lynch syndrome could be considered as a process measure to ensure that patients are receiving the highest quality of care.»

Rather than simply identifying a cancer by location or tissue type, researchers now use advanced molecular profiling tests to characterize tumors, the proteins they express and the novel mutations they develop — known as neoantigens.

Researchers at The Johns Hopkins Kimmel Cancer Center have developed a test for urine, gathered during a routine procedure, to detect DNA mutations identified with urothelial cancers.

Women with particularly aggressive forms of breast cancer could be identified by a test that predicts whether the disease is likely to spread to the brain.

The researchers used a technique called «mutation tracking» — developing a digital PCR test that was personalised to the mutations found in an individual patient's cancer — to identify tumour DNA in the bloodstream.

More than 1800 compounds have been identified in human breath, and tests are being developed for diabetes, cancer, and other afflictions.

Importantly, the research team, funded by Cancer Research UK and the Medical Research Council, have also developed a biomarker test to identify SETD2 mutated tumors, something that can be used immediately in cancer diagCancer Research UK and the Medical Research Council, have also developed a biomarker test to identify SETD2 mutated tumors, something that can be used immediately in cancer diagcancer diagnosis.

For patients with difficult - to - treat cancers, doctors increasingly rely on genomic testing of tumors to identify errors in the DNA that indicate a tumor can be targeted by existing therapies.

Dr Chris Parker, Chair of the NCRI's Prostate Cancer Clinical Studies Group, said: «There's a need to develop better tests to identify and monitor men with aggressive prostate cCancer Clinical Studies Group, said: «There's a need to develop better tests to identify and monitor men with aggressive prostate cancercancer.

The difference with Xalkori is that a test exists to identify that slim percentage of lung cancer patients (about 8,000 people in the United States and 40,000 worldwide each year) who would respond well.

Fortunately, the mutation occurs early in the life of the cancer, so tests like a serum developed by Panacea Pharmaceuticals in Japan may help identify a target early on.

«Once identified, we further tested their role as cancer drivers, for example by looking at molecules with and without mutations and comparing their structure and function,» he adds.

«CD1D performed much better than any other pancreatic secretion marker previously tested in identifying pancreatic cancer,» Dr. Raimondo says.

Professor Widschwendter says: «The data is encouraging since it shows the potential of a blood based epigenetic test to identify breast cancer risk in women without known predisposing genetic mutations.»

Objective To identify common genetic markers that may confer differential benefit from aspirin or NSAID chemoprevention, we tested gene × environment interactions between regular use of aspirin and / or NSAIDs and single - nucleotide polymorphisms (SNPs) in relation to risk of colorectal cancer.

«If we can identify similar genetic loci in people, and if we could find biomarkers for these gene - environment interactions, then perhaps we could develop a simple blood test that identifies people who are at high risk of cancer from low - dose radiation,» says Mao.

Houston Methodist researchers led by Dario Marchetti, PhD, have developed a blood test that can identify circulating tumor cells to predict breast cancer patients at risk for developing brain metastasis.

Professor Paul Pharoah, professor of cancer epidemiology at the Cancer Research UK Cambridge Institute, said: «Our work has found a valuable piece of the puzzle behind ovarian cancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatestcancer epidemiology at the Cancer Research UK Cambridge Institute, said: «Our work has found a valuable piece of the puzzle behind ovarian cancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatestCancer Research UK Cambridge Institute, said: «Our work has found a valuable piece of the puzzle behind ovarian cancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatestcancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatest risk.

The findings also suggest that testing levels of microRNA 135b could help identify patients likely to develop aggressive bowel cancer, and who might need the most intensive treatment.

Testing for these variants combined with all 21 previously identified using genetic sequencing identified men with a 10-fold higher risk of testicular cancer than the population average.

Also today, NHGRI and the National Cancer Institute (NCI), both part of the National Institutes of Health (NIH), announced that all three sequencing centers will devote a significant part of their efforts to The Cancer Genome Atlas (TCGA) Pilot Project, which is testing the feasibility of a large - scale, systematic approach to identify important genomic changes involved in cCancer Institute (NCI), both part of the National Institutes of Health (NIH), announced that all three sequencing centers will devote a significant part of their efforts to The Cancer Genome Atlas (TCGA) Pilot Project, which is testing the feasibility of a large - scale, systematic approach to identify important genomic changes involved in cCancer Genome Atlas (TCGA) Pilot Project, which is testing the feasibility of a large - scale, systematic approach to identify important genomic changes involved in cancercancer.

This personalized medicine approach may be further enhanced by molecular or genetic testing of your cancer, which can help identify treatments that are more effective and / or less toxic.